Procurement Summary
Country : Macedonia
Summary : Laboratory Tests - Mycoplasma, Chlamydia, Helicobacter Pylori, Staphylococcus Test, Streptococcus Test Gr. and other Laboratory Tests
Deadline : 21 Feb 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 96448284
Document Ref. No. : 01612/2024
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Latex agglutination test for identification of Staphylococcus aureus with positive control test 1500, Immunochromatographic test for proving Helicobacter pylori antigen in feces, with a control line, with minimum sensitivity 99.9 %, minimum specificity of 98% test 3000, Qualitative immunochromatographic test for proving Rotavirus/Adenovirus antigens in feces, with a control line, with a minimum sensitivity of 99% and with a minimum specificity of 99% test 150, Test for the detection of HIV antibodies - Rapide test for the detection of antibodies to HIV test 100, Qualitative immunochromatographic testfor the detection of Norovirus antigens in feces, with a control line, with a minimum sensitivity of 95% and with a minimum specificity of 91% test 150, HEMOCULTURES - medium for cultivation, isolation and identification of aerobic, anaerobic microorganisms and yeasts, a medium that can create pressure in a closed villagead when the organism grows. test 100, Test for the identification and proof of Mycoplasma and/or Ureoplasma from urogenital samples Identification of Mycoplasma and/or Ureoplasma by determining the number of live cells in the sample (cfu) and determining sensitivity to at least 12 antibiotics in two concentrationsentries namely: - Tetracyclines (Tetracycline, /Doxycyline, Mincycline) - Macrolides (Erythromycin/Azithromycin, Josamycin, Roxitrhromycin, Clarithromycin) - Quinolones (Levofloxacin, Ciprofloxacin, Ofloxacin) - Lincosamines (Clindamycin), Evidence of Mycoplasma and/or Ureoplasma from uro-genital sampleand through biochemical activity with a substrate that should contain a minimum of 3.64 g/L arginine hydrochloride and a minimum of 3.64 g/L urea. test 2500, Spores for control of dry and wet sterilization with enrichment medium. Strips should have a minimum of 105 or 106 Geobacillus stearothermophilus ATCC7953 spores and 106Bacillus atrophaeus ATCC9372 spores to have a suitable nutrient broth (enriched medium for the growth of sporogenous bacteria that are destroyed at the appropriate temperature, and a change in the color of the medium proves the growth of the bacterium and its presence) for their incubation on a substrate for 24 hours at 600C and 48 hours at 370 C. set (strip set and medium) 300, Rapid serum agglutination test Rose Bengal test Brucella abortus bovis (BAB) test or equivalent test 200, Test for proving and quantifying total anti-Brucella antibodies, in an advanced stage of infection. test 100, Bags for anaerobes, forsingle use, transparent plastic, piece 500, Antiserum Salmonella monovalent 09, pack min 1 ml ml 6, Antiserum Salmonella monovalent 04, pack min 1 ml ml 6, Antiserum Salmonella monovalent 05, pack min 1 ml ml 6, Antiserum Salmonella polyvalent, pack min 1 ml ml 6, Latex agglutination tefor identification of group B streptococci with positive control and agglutination cards test 400, Latex agglutination test for identification of group D streptococci with positive control and agglutination cards test 400, 18.1 Latex agglutination test for identification of streptococci fromgroup A with positive control and cards for agglutination test 2000 18.2 Extraction Enzyme Lyophylized Achromo peptidase lyticen enzym so enzymska activnost od 900-1500 U/mg. Minimalen sostav: Tris-Tris 0.06 w/w, Achromopeptidase 0.45 w/w, Thiomerisal (Merthiolate) 0.60 w/w. coils 20,
CPV Descriptions: Diagnostic Materials, Laboratory Reagents, Medical Equipment, Pharmaceutical and Personal Care Products
Documents
Tender Notice
Document_1.docx
Document_2.pdf